Recurrent miscarriage that has no explanation is a specific kind of exhausting. You’ve done the investigations. The anatomy is normal. The chromosomes are normal. The clotting profile is normal. Your doctor uses the word “unexplained” and you understand what it means clinically, but emotionally it lands as: we don’t know, and we don’t know what to do next.
LIT sits in that gap. It’s not a mainstream fertility treatment. It’s not offered everywhere, and it attracts more debate than most interventions in reproductive medicine. But for a specific subset of patients with immunological recurrent pregnancy loss, it represents a genuine clinical option that deserves a clear, honest explanation rather than either uncritical promotion or reflexive dismissal.
What LIT Is and Why It Exists
LIT stands for Lymphocyte Immunisation Therapy, sometimes called paternal lymphocyte immunisation therapy because the white blood cells used in the treatment are typically drawn from the partner.
The theory behind it connects to a well-established immunological principle: a successful pregnancy requires the maternal immune system to tolerate the embryo, which is genetically foreign, carrying paternal DNA. In most pregnancies, this tolerance develops naturally. The maternal immune system recognises paternal antigens, mounts a regulatory response, and the pregnancy is protected rather than rejected.
In some women with recurrent pregnancy loss, this tolerance mechanism may not function correctly. The immune system may recognise the embryo as foreign and mount a response that disrupts implantation or early placentation, leading to miscarriage. The hypothesis underlying LIT is that exposing the maternal immune system to paternal lymphocytes before pregnancy, through a series of injections under the skin, primes the regulatory immune response and increases the likelihood of successful tolerance when pregnancy occurs.
This is immunotherapy for recurrent pregnancy loss, applied specifically to the implantation and early pregnancy context.
What the Treatment Involves
LIT treatment for recurrent miscarriage follows a defined protocol. Blood is drawn from the male partner and processed to isolate lymphocytes. These are then injected intradermally into the female partner’s forearm, typically in a series of small injections at multiple sites. The procedure takes about 30 minutes and is performed in a clinical setting.
The protocol usually involves an initial sensitisation course of two to three injections, spaced several weeks apart, followed by a booster dose before the pregnancy attempt and sometimes during early pregnancy. The female partner is tested for antibody responses before the cycle begins, specifically anti-paternal cytotoxic antibodies, to assess whether she has developed the expected immunological response.
Lymphocyte immunisation therapy in Hyderabad at specialised centres follows this structured protocol. The antibody testing component is important: if there is no antibody response to the injections, the treatment may not be achieving the intended immunological effect, which changes the clinical conversation about whether to continue.
Who It’s Intended For
LIT is not a treatment for all recurrent miscarriage. It’s specifically aimed at a subset of patients where immunological factors are suspected as the underlying cause. The profile that most frequently comes up in clinical discussions:
Women with three or more unexplained first-trimester miscarriages where structural, chromosomal, hormonal, and thrombophilic causes have been excluded. Women with recurrent implantation failure in IVF, where embryo quality and timing have been confirmed as adequate. Women with a history suggesting immune-mediated pregnancy loss, including unexplained elevated NK cell activity or skewed cytokine profiles on immune panel testing.
It’s also worth stating clearly who LIT is not for: women whose miscarriages are explained by chromosomal factors, antiphospholipid syndrome, uterine abnormalities, or thrombophilias. These have their own treatments. LIT is not a catch-all for recurrent pregnancy loss. It’s a targeted intervention for a specific immunological hypothesis.
Two Hypothetical Profiles That Illustrate the Decision
Consider a hypothetical patient with four unexplained miscarriages, all in the first trimester, with a complete negative workup: normal karyotype for both partners, normal hysteroscopy, negative antiphospholipid antibodies, normal thrombophilia screen, and normal thyroid function. Immune panel testing reveals elevated uterine NK cell activity. In a profile like this, immunotherapy for recurrent pregnancy loss is a clinically coherent next step. The standard investigations have excluded the usual causes. The immune panel has identified a possible mechanism. LIT is recommended as part of a broader immune-modulating protocol alongside progesterone support and low-dose aspirin. The rationale is specific and documented, not speculative.
Now consider a different hypothetical: a patient with two miscarriages, one of which was confirmed chromosomally abnormal on products of conception testing. Her investigations are otherwise incomplete. LIT is discussed at her consultation. The clinical recommendation is against it at this stage. Two losses, one of which has a chromosomal explanation, does not constitute unexplained recurrent miscarriage. Recommending immunotherapy before a complete standard workup is completed and before a third loss has occurred is premature. The treatment has a cost and a protocol duration, and carries the risk that a real underlying cause goes uninvestigated while attention focuses on an unconfirmed immunological hypothesis.
The Evidence: Honest Assessment
The evidence base for LIT is more contested than clinics offering it sometimes acknowledge. Several randomised controlled trials have shown benefit in specific recurrent miscarriage populations. Others have not. A Cochrane review published in the early 2000s found insufficient evidence to recommend LIT as a standard treatment. More recent data, including meta-analyses, suggests benefit in well-selected patients, particularly those with elevated NK cell activity or demonstrated absence of anti-paternal antibodies.
The LIT treatment success rate in India, as reported by centres offering the treatment, varies considerably, partly because patient selection criteria differ between centres, and partly because outcome definitions vary. Reported live birth rates in treated patients range from 70 to 85% in published case series from centres with rigorous selection protocols. These figures need to be interpreted carefully: without a matched control group, it is difficult to separate the effect of LIT from the effect of close monitoring, progesterone support, and the other co-interventions typically used alongside it.
The honest position is this: LIT is not proven beyond doubt, but it is part of mainstream medicine. It has a biological rationale, a defined patient population, and a body of evidence that is mixed but not dismissive. For patients who have exhausted standard explanations and treatments, it represents a legitimate option worth discussing with a specialist who can assess whether the immunological profile supports its use.
Unexplained Recurrent Miscarriage Treatment: Why LIT Is Not the Only Lever
LIT is rarely used in isolation at centres with genuine expertise in recurrent pregnancy loss. The treatment almost always sits within a broader protocol that includes progesterone supplementation from ovulation, low-dose aspirin, close early pregnancy monitoring with serial beta-hCG and early ultrasound, and often additional immune modulation with steroids or intralipid infusion depending on the immune panel findings.
The value of this comprehensive approach is that multiple potential mechanisms are addressed simultaneously, which is clinically appropriate when the diagnosis is multifactorial or incompletely understood. The risk is that when a pregnancy succeeds within such a protocol, attributing the success specifically to LIT versus the other interventions is difficult.
At 9M Fertility, LIT treatment for recurrent miscarriage is offered within a full recurrent pregnancy loss workup, not as a standalone first response. The immune panel findings, the number and timing of prior losses, and the results of standard investigations all inform whether LIT is recommended and in what combination with other supportive treatments.
The Part That Doesn’t Get Said Enough
Patients considering LIT for unexplained recurrent miscarriage are almost always in a state of significant grief and urgency. They want an answer. They want something to try. LIT can feel like the answer because it comes with a mechanism, a protocol, and a treatment timeline.
The responsibility of a good fertility specialist in this situation is to hold that urgency carefully without exploiting it. LIT may be the right next step. It may also be premature if the workup is incomplete, inappropriate if the immune panel does not support it, or less helpful than another intervention if a cause has been missed.
The question worth asking any clinic that recommends LIT is, “What specific finding in my case makes you think this is the right treatment?” The answer should be specific. If it isn’t, ask again.
Book a consultation at 9M Fertility to discuss whether immunotherapy for recurrent pregnancy loss is appropriate for your specific profile.
→ Also read: ERA Test in IVF: How It Helps Find Your Perfect Embryo Transfer Window
→ Also read: PGT-A Testing: How Genetic Screening Can Improve Your IVF Success Rate
